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Purpose: The aim of this study was to determine the genetic cause
of autosomal dominant nonsyndromic hearing loss segregating in a
multigenerational family.
Methods: Clinical examination, genome-wide linkage analysis,
and exome sequencing were carried out on the family.
Results: Affected individuals presented with early-onset progres-
sive mild hearing impairment with a fairly flat, gently downsloping
or U-shaped audiogram configuration. Detailed clinical examina-
tion excluded any additional symptoms. Linkage analysis detected
an interval on chromosome 1p21 with a logarithm of the odds
(LOD) score of 8.29: designated locus DFNA37. Exome sequencing
identified a novel canonical acceptor splice-site variant c.652-2A>C
in the COL11A1 gene within the DFNA37 locus. Genotyping of all
48 family members confirmed segregation of this variant with the
deafness phenotype in the extended family. The c.652-2A>C variant
is novel, highly conserved, and confirmed in vitro to alter RNA
splicing.
Conclusion: We have identified COL11A1 as the gene responsible
for deafness at the DFNA37 locus. Previously, COL11A1 was solely
associated with Marshall and Stickler syndromes. This study
expands its phenotypic spectrum to include nonsyndromic deaf-
ness. The implications of this discovery are valuable in the clinical
diagnosis, prognosis, and treatment of patients with COL11A1
pathogenic variants.
Genetics in Medicine (2019) 21:948–954; https://doi.org/10.1038/s41436-
018-0285-0
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INTRODUCTION
Hereditary hearing loss is a genetically heterogeneous
disorder with over 150 genes implicated. Mirroring the
genetic complexity is the breadth of phenotypic manifesta-
tions associated with pathogenic variants in these genes as
more than 20% exhibit an extraordinary pleiotropy: they can
give rise to either autosomal dominant nonsyndromic hearing
loss (ADNSHL) or autosomal recessive nonsyndromic hear-
ing loss (ARNSHL) (e.g., TECTA and TMC1) and they can
cause syndromic hearing loss or nonsyndromic hearing loss
(NSHL) (e.g., Usher type 1–causing genes, WFS1, TBC1D24,
and COLL11A2) (refs. 1–6).
The collagen family is diverse and consists of more than 20
genetically distinct genes. Collagens are fibrous structural
proteins involved in the construction of skin, cartilage, bone,
eye, and other tissues.7,8 All collagen molecules are comprised of
three α-chain subunits tightly wrapped into a triple helix. The
composition of each triple helix either contains one, two, or
three different types of α-chains. For instance, the α-chains
encoded by COL11A1, COL11A2, and COL2A1 comprise a
unique collagen fibril that is essential for proper skeletal and
cartilage formation as well as ocular and auditory function.6,9,10
The COL11A1 gene, located on chromosome 1p21.1,
consists of 67 exons spanning 232 Kb.11 It encodes a peptide
consisting of N- and C-terminal propeptides surrounding a
collagen α-chain following the typical collagen Gly-X-Y repeat
configuration. In the inner ear type XI collagens localize to the
tectorial membrane, a gelatinous sheet-like structure
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anchored to the apex of the interdental cells. The tectorial
membrane lies on top of sensory hair cells and is comprised of
four distinct types of collagen (types II, V, IX, and XI) and
three primary noncollagenous glycoproteins (α-tectorin;
Tecta, β-tectorin; Tectb, and Otogelin).12
Pathogenic variants in COL11A1 have been linked to
specific genetic disorders of the connective tissue, namely
Marshall syndrome (MRSHS),13 Stickler syndrome type II
(STL2) (refs. 14,15), and fibrochondrogenesis (FBCG1) (ref. 16).
Fibrochondrogenesis is an ultrarare disorder inherited in an
autosomal recessive fashion. Affected individuals have severe
skeletal defects characterized by pear-shaped vertebral bodies
and broad long-bone metaphyses. Both Marshall and Stickler
type 2 syndromes are rare autosomal dominant disorders.
Clinically, there is much overlap between the two disorders
because both include less severe vertebral and long-bone
abnormalities; midface hypoplasia, which may include cleft
palate; myopia with beaded vitreous; and mild to moderate
hearing loss.
Until now, pathogenic variants in COL11A1 have been
exclusively linked to syndromic deafness. In this study, we
present a novel splice-site altering variant in COL11A1 that
segregates in a large family with postlingual progressive
ADNSHL and thus expands the phenotypic spectrum of
pathogenic variants in COL11A1.
MATERIALS AND METHODS
Patients and clinical data
A four-generation family of European descent was ascertained
as part of a genetic study of dominant progressive hearing loss
at Boys Town National Research Hospital (BTNRH) between
the years 1990 and 2000. After obtaining written informed
consent from all participants with approval by the Institu-
tional Review Board of BTNRH, pure tone audiograms and
medical information were collected from participating family
members. Clinical examination of the subjects excluded any
additional syndromic findings. Blood samples from 48 family
members were obtained and initial linkage studies were
performed. The current studies were approved by the
institutional review boards at the University of Nebraska
Medical Center (UNMC) and the University of Iowa.
Audiograms and data analysis
Pure tone audiometry was performed according to current
standards to determine air conduction thresholds at 0.25, 0.5, 1,
2, 4, 6, and 8 kHz. Bone conduction thresholds were determined
at some frequencies in some patients to exclude conductive
hearing impairment. After validating binaural symmetry, the
binaural mean air conduction threshold (dB hearing level, HL)
at each frequency was used for further analyses. Conduction loss
was recorded for some individuals. For this reason the threshold
data from individual IV:12 were excluded, as well as those
obtained at age 6 years from individual III:17, and those
obtained from the left ear in individual III:4.
Linear regression analyses of threshold on age were used to
evaluate progression of hearing impairment at the separate
audio frequencies. These analyses comprised both individual
longitudinal data derived from serial audiograms, and overall,
cross-sectional last-visit data.17 Progression was called
significant if the 95% confidence interval (95% CI) for slope
did not include zero at two or more frequencies (out of 6 or 7,
which is significant at p < 0.05 according to binomial
distribution statistics, with p= 0.025 and q= 0.975 for
positive correlations). The same applies to the threshold
intercept. Progression was expressed in dB per year, and
designated annual threshold deterioration (ATD). It was
checked that the cross-sectional regression data conformed to
the individual longitudinal regression data. Following that
check, the regression data bearing on the last-visit thresholds
were used to derive age-related typical audiograms (ARTA),
which show the expected thresholds for a number of decade
steps in age.17
Cross-sectional linear regression analyses were repeated for
plots of threshold –P50presby against age, where P50presby is
the median presbyacusis predicted by the ISO 7029 norm18
according to each patient’s gender and the age at which the
audiogram was obtained.
Linkage analysis
Genome-wide linkage analysis was first conducted with
microsatellite markers using an ABI Prism linkage mapping
set and results were confirmed using the Affymetrix Xba chip
(Affymetrix, Santa Clara, CA) with 50,000 single-nucleotide
polymorphism (SNP) markers.19 Genotype calls were made
with the BRLMM algorithm. Parametric multipoint linkage
analysis was carried out using the Merlin program.
Exome sequencing and bioinformatic analysis pipeline
Four affected individuals (II.6, II.9, II.11, and III.9) underwent
exome sequencing (ES) using the Agilent SureSelect Human All
Exonv5 Kit (Agilent Technologies, Santa Clara, CA) as
described2,20 (Fig. 1a). Prepared libraries were pooled and
sequenced using an Illumina Hiseq 2000 (Illumina, San Diego,
CA). We analyzed ES data using a custom bioinformatic
pipeline. Reads were aligned to human reference genome
(Human GRCh37/hg19) using Burrows–Wheeler Aligner
(BWA). Variant calling was performed two ways: initially with
the conservative Genome Analysis Toolkit (Broad Institute,
Cambridge, MA), and later with the more inclusive SAMtools
mpileup. Variants were annotated for conservation and
deleteriousness using dbNSFP v2.0 (ref. 21), and for minor
allele frequency (MAF) using the 1000 Genomes Project
database, the Exome Aggregation Consortium database (ExAC)
(http://exac.broadinstitute.org/), and the Genome Aggregation
Database (gnomAD) (http://gnomad.broadinstitute.org/). Var-
iant predicted effects on splicing were assessed using Human
Splicing Finder (http://www.umd.be/HSF3/).
The following criteria were used for variant filtering: quality
(depth ≥10×, Quality of Depth (QD) >5, quality >30), MAF
<0.0001, coding effect (nonsynonymous, indels, and splice-site
variants), heterozygosity, and allele sharing amongst sequenced
affected individuals.
BOOTH et al ARTICLE
12
34
56
78
9
0(
):,
;
GENETICS in MEDICINE | Volume 21 | Number 4 | April 2019 949
Segregation analysis
Sanger sequencing was completed in available family members
to confirm segregation of all candidate variants (Table S1);
c.652-2A>C in COL11A1 gene (MIM 120280; NM_080629.2),
c.70C>T:p.R24W in ARHGEF16 (NM_014448.3), and
c.847G>A:p.E283K in TRABD (NM_001320484.1).
Minigene splicing assay
In vitro minigene assays were carried out as described.22
Briefly, wild-type exon 5 and ~120 base pairs of each
flanking intron of COL11A1 were polymerase chain reaction
(PCR) amplified and ligated into the pET01 vector
(MoBiTec, Goettingen, Germany). The c.652-2A>C variant
was introduced to the wild-type vector using the Quik-
Change Lightning Site-Directed Mutagenesis kit (Agilent,
Santa Clara, CA, USA) according to the manufacturer’s
protocol. Wild-type or mutant vectors were transfected into
COS7 and HEK293 cells in triplicate. Total RNA was
harvested 48 h posttransfection and complementary DNA
(cDNA) was transcribed according to the manufacture
protocol. PCR using primers specific to the 5′ and 3′ native
exons of the pET01 vector was performed and products
were visualized on an agarose gel. Gel products were
extracted and Sanger sequenced.
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Fig. 1 Genetic Analysis of c.652A>C variant in COL11A1. a Family pedigree showing the segregation of the c.652-2A>C variant in COL11A1. Red and
bold indicates the mutant allele. Circles and squares represent females and males, respectively. Filled symbols denote individuals with nonsyndromic hearing
loss (NSHL) and nonfilled symbols show individuals with normal hearing. b Age-related typical audiograms (ARTA). Binaural mean air conduction thresholds
(dB HL) are presented for the ages 10–60 years. c Parametric linkage analysis plot of chromosome 1. d Representative chromatograms from wild-type and
mutant sequences. e Gel electrophoresis of wild-type COL11A1 exon 5, c.652-2A>C pathogenic variant, and the empty pET01 vector. The inclusion of exon
5 results in a 372-bp product and its exclusion results in a 234-bp band. Sequence chromatograms show read through at each exon junction. Results shown
from COS7 experiments. LOD logarithm of the odds.
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RESULTS
Clinical presentation
The family ascertained in this study is a four-generation
kindred of European descent segregating hearing loss as an
autosomal dominant trait (Fig. 1a). Pure tone audiometric
evaluation of affected members showed bilateral, postlingual,
progressive sensorineural hearing loss (Fig. 1b). The hearing
loss was mild to moderate and progressed slowly. The finding
of a significant threshold intercept at age 0 years (Figure S2) at
all frequencies except 8 kHz (Figure S2) suggests the presence
of a substantial congenital component (of 12 to 23 dB) to the
SNHL. As shown by the ARTA depicted in Fig. 1b, the mean
audiogram configuration developed from U-shaped (mid-
frequency type) to flat with advancing age up to ~40 years. At
more advanced ages it remained flat or became very gently
downsloping (Fig. 1b, S1).
To evaluate progression of hearing impairment at each
frequency, we performed linear regression analyses of
threshold on age. The resulting ATD (progression) was
significant at 5 of 7 frequencies (significant): 0.25–1 kHz, 4
and 8 kHz. It varied between 0.2 and 0.8 dB per year
(Figure S2). This variation is also reflected by the ARTA
(Fig. 1b). One-way analysis of variance (ANOVA) followed by
Tukey’s multiple comparison test showed that the ATD at 2
kHz was significantly smaller than the ATD at all other
frequencies, whereas the ATD at 8 kHz was significantly
greater than the ATD at all other frequencies, except for 0.25
and 4 kHz. The ATD for the thresholds corrected for median
presbyacusis was significantly positive at 0.25–1 kHz (Fig-
ure S3). This suggests SNHL progression beyond presbyacusis
at these lower frequencies. The ATD at the higher frequencies
did not differ significantly from zero, even though the values
at 6–8 kHz were negative. This implies that progression at
2–8 kHz conformed with expected presbyacusis. Clinical
examination of affected members excluded any additional
syndromic features usually associated with Marshall syn-
drome and Stickler syndrome as the craniofacial features of
affected family members were normal. X-ray images of the
long bones of the proband (III-19) were also normal. There
was no history of ocular abnormalities or cleft palate in the
family.
Linkage analysis
The initial linkage analysis identified a single region on
chromosome 1p21 spanning ~12Mb between markers
D1S497 and D1S2651 with a maximum LOD score of 8.29
for marker D1S195 (ref. 19). This linked interval was
designated DFNA37. A second genome-wide linkage using
the Affymetrix Xba chip narrowed down the linked interval to
a ~8.4 Mb region between markers rs724480 and rs6667402
(Fig. 1c, S4).
Exome sequencing and variant assessment
Capitalizing on the advances made in sequencing technolo-
gies, we used ES to screen four affected individuals (II.6, II.9,
II.11, and III.9). An average depth of coverage of 114 reads
was obtained with 92% of targeted regions covered at ≥30×
(Table S2). After filtering for quality, MAF, coding effect
(nonsynonymous, indels, and splice-site variants), hetero-
zygosity, and allele sharing amongst sequenced affected
individuals in the DFNA37 locus, only one variant in
COL11A1 was identified. The variant NM_080629.2; c.652-
2A>C (chr1:103496802T>G) affects the canonical splice site
in intron 4 resulting in the alteration of the acceptor site (AG
to CG) confirmed by analysis with Human Splicing Finder 3.0
and NNSPLICE 0.9. Sanger sequencing performed on all
family members showed the segregation of c.652-2A>C
variant at a heterozygous state with the deafness phenotype
in the extended family (Fig. 1a, d). This splice-site variant is
predicted to cause skipping of exon 5 and a production of a
protein lacking residues 218–260 in the N-propeptide
domain.
Splicing analysis
To characterize the impact of the c.652-2A>C variant on RNA
splicing, we cloned the wild-type and mutant sequences of
COL11A1 exon 5 and flanking introns into the pET01 exon
trap vector and transfected them into two different cell lines.
Visualization of the splicing products revealed that cells
transfected with the wild-type vector yielded the expected
372-bp band containing exon 5 (Fig. 1e). In contrast, cells
transfected with the mutant vector yielded two bands; one at
372 bp corresponding to the wild-type allele and the second at
234 bp lacking exon 5. These results were identical across both
cell lines. Sequencing all bands confirmed break points and
splicing events.
DISCUSSION
Coupling linkage analysis and ES, we identified a novel splice-
site altering variant (c.652-2A>C) in the COL11A1 gene
segregating in a large European-American pedigree with
postlingual progressive ADNSHL. The DFNA37 locus was
mapped almost two decades ago but screening methodologies
at the time failed to detect causative alterations in COL11A1
(ref. 19). Since mapping of DFNA37, knowledge of genomic
sequences has improved substantially. In addition, develop-
ment of next-generation sequencing has proven useful in
elucidating the genetic causes of Mendelian disorders and
notably, hereditary deafness.23 We capitalized on these new
technologies to reevaluate the DFNA37 locus for pathogenic
variants and identified the genetic cause underlying hearing
loss in this family.
The heterozygous c.652-2A>C variant in COL11A1 we
identified segregating with the NSHL in this family is novel
(absent from all population databases), highly conserved, and
predicted to abolish the acceptor splice site of exon 5 by in
silico analysis. We confirmed aberrant splicing of exon 5 due
to c.652-2A>C in vitro using a minigene splicing assay
(Fig. 1e). Interestingly, the c.652-2A>C variant seems to affect
splicing efficiency rather than completely abolishing it. These
findings suggest the c.652-2A>C variant creates a leaky
acceptor splice site that allows for some expression of a
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normal spliced transcript. This might explain the audiometric
variability seen among some affected individuals, such as the
manifestation of conductive hearing loss seen in III.4 and
IV.12 or the diversity of audiometric configurations between
individuals which could be flat, gently downsloping or U-
shaped (Figure S1). Exon 5 is the last exon before the start of
the variable region (exons 6, 7, 8, and 9) thus the c.652-2A>C
variant would affect splicing in all five transcripts of COL11A1
(Fig. 2). Aberrant splicing leading to exon 5 skipping would
result in an in-frame deletion and COL11A1 peptides lacking
residues 218–260 in the N-terminal propeptide (Fig. 2). It is
also possible that other splicing events occur that could not be
detected with the current minigene design. Analysis of
RNA from individuals harboring the c.652-2A>C variant
would better define the splicing defects resulting from this
variant.
The exact function of N-terminal propeptide remains
unclear. However, it is known to have a role in regulating
the shape and size of the collagen fiber.24 Lacking the amino
acids encoded by exon 5 could result in a collagen fibril with a
different diameter or shape, due to loss of key N-terminal
propeptide regulatory sequences, such as the heparan sulfate
binding motif that is located between residues 147–152
(refs. 25,26). Alternatively, it may result in protein misfolding
as this domain also houses two structurally important cysteine
residues at amino acids 236 and 243, which are important to
disulfide bond formation with other cysteines at positions 182
and 61. In the inner ear, COL11A1 is expressed in the tectorial
membrane. Within the tectorial membrane, collagens form
two networks of fibers: one unbranched, parallel, and
coordinated mainly by noncollagenous proteoglycans. The
second, a striated sheet structure, is orientated via the cross
bridges and glycoproteins. Loss of this organization at either
the collagenous or noncollagenous level causes hearing loss in
mice and humans.5,27 Because the N-propeptide domain plays
a role in the establishment of molecular interactions with
several extracellular matrix molecules and cellular proteins
such as heparan sulfate proteoglycans and calcium, its
alteration might impair its binding affinity for these
molecules.25,28 This could hamper interactions between cells
and the surrounding extracellular matrix, as well as interac-
tions between the diverse constituents of the extracellular
matrix.
Regardless of the variant effect, it is clear the residues
encoded by exon 5 are essential for proper auditory function.
The absence of any other phenotypic manifestations in the
described family is remarkable, given all previously reported
autosomal dominant pathogenic variants (>50) have been
only associated with either STL2 or MRSHS (Fig. 2).
However, the splice-site variant identified in this study is
the first pathogenic alteration reported in the nonvariable
region of the N-propeptide domain. The majority of
pathogenic variants in COL11A1 are splice-altering located
in the triple-helical domain and thought to exert their effect
via a dominant–negative mechanism. This is further sup-
ported by studies in mouse showing that mice homozygous
for a spontaneous frameshift pathogenic variant in Col11a1
have severe chondrodysplasia and die at birth. Heterozygous
mice escape lethality, develop osteoarthritis, and have normal
auditory responses up to 10 months postnatally.29 The lack of
an auditory phenotype in the heterozygous mouse suggests
haploinsufficiency is not the pathogenic mechanism
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Fig. 2 COL11A1 gene and protein schematic denoting reported pathogenic variants and their associated phenotypes. All variants were collected
from the Deafness Variation Database (DVD; http://deafnessvariationdatabase.org/). The gray box shows the alternatively spliced exons. Text colored blue,
black, green, and orange indicates the phenotypes associated with pathogenic variants in COL11A1: STL2, FBCG1, MRSHS, and STL2/MRSHS, respectively.
Missense variants are in italics and nonsense variants are underlined. An asterisk (*) denotes a synonymous change, while a double asterisk (**) represents
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site is noted as +1 using transcript NM_001854.3.
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underlying COL11A1-related auditory defects in humans.
Pleiotropy associated with deafness-causing genes, where
pathogenic variants in the same gene could cause either
syndromic or nonsyndromic hearing loss, has been demon-
strated for several other genes such as the genes involved in
Usher syndrome (PCDH15; DFNB23/USH1F, USH1C;
DFNB18A/USH1C, WHRN; DFNB31/USH2D, MYO7A;
DFNB2/DFNA11/USH1B, CDH23; DFNB12/USH1D),
WFS1 (DFNA6/14/38/Wolfram syndrome), TBC1D24
(DFNA65/DFNB86/DOORS syndrome), and COLL11A2
(DFNB53/DFNA13/STL3) (refs.1–3,5).
The present DFNA37 patients with a COL11A1 pathogenic
variant showed fairly similar audiograms to those reported
for DFNA traits with a midfrequency type of hearing
impairment: DFNA8/12 (TECTA) and DFNA13 (COL11A2)
(refs. 30,31). The DFNB phenotypes that are allelic to these
traits also show midfrequency-like types of audiograms, but
usually at substantially higher thresholds: DFNB21 (TECTA)
and DFNB53 (COL11A2) (refs. 32,33). Patients with collage-
nopathies that include hearing impairment due to deleterious
variants in COL11A1 (STL2 and Marshall syndrome) and
COL11A2 (STL3) also show remarkably similar types of
audiograms.34–36 The results of psychophysical tests at
suprathreshold levels in DFNA8/12, DFNA13, and STL3
(COL11A2) patients revealed that the type of hearing
impairment is compatible with intracochlear conduction
loss.36–38 This is in line with the notion that disease-causing
variants in COL11A2 affect tectorial membrane function.31,39
Recent work on cochlear (micro)mechanics involving animal
models with genetic modifications has provided compelling
evidence about the relevant mechanical changes that can be
involved.5,12,39
In summary, here we report the clinical and genetic
characteristics associated with deafness at the DFNA37 locus
and we expand the spectrum of COL11A1-associated
phenotypes to include ADNSHL. This study illustrates
another example of the pleiotropy exhibited by other
deafness-causing genes and highlights the complexity asso-
ciated with providing the correct genetic diagnosis.
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